CyDex Pharmaceuticals, Inc.

CyDex Pharmaceuticals Initiates Dosing for Phase 2A Oncology Drug Trial

Published in Cancer Weekly, April 6th, 2010

CyDex Pharmaceuticals, Inc. announced the initiation of patient dosing in the company's Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL (CDX-353). Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.

The trial will compare the pharmacokinetics of CyDex's CDX-353: Propylene Glycol-Free Melphalan HCL for Injection with Alkeran for Injection and evaluate safety parameters. CyDex is working in partnership with The University of Kansas Cancer Center on the trial, which will be partially funded by a grant the company received from the Kansas Bioscience...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2010-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry